Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III neoadjuvant KN026 + HB1801 ± carboplatin versus trastuzumab + pertuzumab + docetaxel ± carboplatin in HER2-positive early or locally advanced breast cancer
CTR20244675Phase 3Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Dec 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of anbenitamab, albumin-bound docetaxel, trastuzumab, pertuzumab, docetaxel and 1 more in breast cancer (2 arms), sponsored by Shanghai Jinmante Biotechnology Co., Ltd. Primary endpoint: Total pathologic complete response. Started Dec 2024; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20244675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244675.